Welcome to our dedicated page for Alphatec Holdings news (Ticker: ATEC), a resource for investors and traders seeking the latest updates and insights on Alphatec Holdings stock.
Alphatec Holdings, Inc. (ATEC) is a leading medical technology company specializing in innovative spine surgery solutions. Our primary focus is the design, development, launch, and delivery of spinal fusion products aimed at improving patient outcomes. By collaborating with spine surgeons, we create and develop products and systems that address the entire spinal fusion procedure, enhancing efficiency and effectiveness.
At Alphatec Spine, we are committed to driving growth through constant innovation. Our product portfolio includes advanced technologies such as Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion. Each of these solutions is designed to simplify surgical procedures for surgeons, ultimately leading to superior patient outcomes.
We pride ourselves on our relentless pursuit of superior outcomes. By continuously developing technologies that positively impact patient care, we strive to be at the forefront of the medical technology industry. Our mission is to improve lives by providing cutting-edge spine surgery solutions.
For more detailed information about our products and ongoing projects, please visit our website at www.alphatecspine.com.
Latest News:
- --- Source: Alphatec Holdings, Inc.
- ---
- ---
- Source: Spineology Inc.
- ---
- ---
Paragon 28 (NYSE: FNA), a foot and ankle surgical solutions provider, has appointed Dave Demski as an independent director, expanding its board from eight to nine members. Demski brings over two decades of orthopedic executive leadership experience, having most recently served as President and CEO of Globus Medical from 2017 to 2022. His background includes roles as CFO, COO, and President of Emerging Technologies at Globus Medical. Currently, he serves on the board of Alphatec Spine and previously served on Axonics' board until its acquisition by Boston Scientific in 2024. Demski holds a B.S. in Business Administration from the University of Michigan and an MBA from Stanford.
Alphatec Holdings (Nasdaq: ATEC) has announced its upcoming participation in the J.P. Morgan Healthcare Conference. The spine surgery solutions provider will deliver a presentation at the Westin St. Francis Hotel in San Francisco on January 15, 2025, at 5:15 PM Pacific Time.
The company will make both the webcast and presentation materials accessible through the Investor Relations section of their website, allowing interested parties to follow the presentation remotely.
Alphatec Holdings (ATEC) reported strong Q3 2024 results with total revenue reaching $151 million, driven by 30% surgical revenue growth and 27% total revenue growth. The company achieved a GAAP gross margin of 68% and recorded a GAAP net loss of $40 million. Key operational highlights include 20% procedural volume growth, 19% growth in new surgeon adoption, and over 200 surgeon training engagements. ATEC secured a $50 million expansion of its existing term loan facility, bringing total capacity to $200 million. The company raised its full-year 2024 guidance, now expecting total revenue of $605 million and adjusted EBITDA of $27 million.
Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative spine surgery solutions, has announced it will report its third quarter 2024 financial results on October 30, 2024, after market close. The company will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day.
To access the webcast, investors can visit the Investor Relations Section of ATEC's Corporate Website. For those wishing to dial in, registration is required via a provided link. A replay of the webcast will be available for twelve months.
Additionally, ATEC has granted 49,969 restricted stock units (RSUs) to 12 new non-executive employees as an employment inducement. These RSUs will vest in equal annual installments over four years, subject to continued employment, and will fully vest upon a change of control of ATEC.
Alphatec Holdings (Nasdaq: ATEC) will showcase its informatics-integrated spine procedures at the North American Spine Society (NASS) 29th Annual Meeting from September 25-27, 2024, in Chicago. The company will highlight its approach-specific technologies coupled with proprietary informatics like EOS Insight and SafeOp to improve spine surgery outcomes. Key presentations include a demonstration of ATEC's Prone TransPsoas (PTP) Approach and discussions on lateral surgery evolution and EOS Insight's impact on deformity surgery durability.
Additionally, ATEC granted 38,374 restricted stock units (RSUs) to 14 new employees as employment inducements, vesting over four years or fully upon a change of control.
Alphatec Holdings (NASDAQ:ATEC) reported strong Q2 2024 financial results, with total revenue growing 25% to $146 million. Surgical revenue increased by 27%, driving overall growth. The company has raised its full-year guidance, now expecting total revenue to grow 25% to $602 million and non-GAAP adjusted EBITDA of approximately $25.5 million.
Key highlights include the launch of EOS Insight™, expansion in major markets, 20% growth in new surgeon adoption, and the appointment of Keith Valentine to the Board of Directors. ATEC achieved profitability milestones and continues to focus on self-funded growth. The company's strategic initiatives and spine-focused approach are yielding positive results, positioning ATEC for continued success in the spine surgery market.
Alphatec Holdings (ATEC), a spine surgery solutions provider, announced its participation in four upcoming investor conferences:
- RBC West Coast Medical Device Bus Tour on August 14, 2024
- Piper Sandler MedTech and Diagnostics California Bus Tour on August 21, 2024
- Morgan Stanley Global Healthcare Conference on September 4, 2024
- Wells Fargo Healthcare Conference on September 5, 2024
Live webcasts, if available, will be accessible on ATEC's Investor Relations website. Additionally, ATEC granted 44,772 restricted stock units (RSUs) to 22 new non-executive employees as employment inducement. These RSUs will vest over four years and fully upon a change of control.
ATEC (Nasdaq: ATEC) has launched EOS Insight, an innovative end-to-end spine surgery platform powered by EOSedge scans and AI. The first EOS Insight-informed surgeries were successfully performed at OrthoIndy Hospital. This groundbreaking platform leverages AI to provide important information throughout multiple stages of spine care, including:
- AI-driven alignment calculation
- 3D-surgical planning simulations
- Patient-specific rods
- Intra-operative reconciliation
- Post-operative analytics
EOS Insight aims to modernize spine surgery by replacing archaic clinical practices and improving patient outcomes. The platform's ability to automate processes and integrate alignment data into surgical plans positions ATEC as a potential standard-bearer in spine care.
Alphatec Holdings (Nasdaq: ATEC) announced it will report its Q2 2024 financial results on July 31, 2024, after the market close. A live webcast will be hosted at 1:30 p.m. PT / 4:30 p.m. ET, accessible through the Investor Relations section of the company's website. Participants can dial into the webcast after registering online, and a replay will be available for twelve months.
In related news, ATEC's independent Compensation Committee approved inducement grants for 30 new employees, totaling 47,112 restricted stock units (RSUs). These RSUs will vest annually over four years, contingent on continuous employment, and will fully vest upon a change of control of the company.
Alphatec Holdings, Inc. (Nasdaq: ATEC) reported a 27% growth in total revenue to $138 million, with 30% increase in surgical revenue. Adjusted EBITDA margin expanded by 450 basis points. Full-year revenue and adjusted EBITDA guidance raised to $601 million and $23 million respectively. The company experienced growth in surgical revenue, surgeon adoption, and U.S. footprint expansion. Ending cash balance was $144 million. Non-GAAP gross margin was 71%. The CEO expressed confidence in the company's future growth potential.
FAQ
What is the current stock price of Alphatec Holdings (ATEC)?
What is the market cap of Alphatec Holdings (ATEC)?
What does Alphatec Holdings, Inc. specialize in?
What are some of the key technologies developed by Alphatec Spine?
How does Alphatec Holdings, Inc. improve spine surgery procedures?
What is the mission of Alphatec Holdings, Inc.?
How does Alphatec Holdings, Inc. drive growth?
Where can I find more information about Alphatec Holdings, Inc.?
What recent achievements has Alphatec Holdings, Inc. made?
What are the main products of Alphatec Holdings, Inc.?
How does Alphatec Holdings, Inc. ensure superior patient outcomes?
Is Alphatec Holdings, Inc. involved in any partnerships?
